NCT06683300Not yet recruiting
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
Source: ClinicalTrials.gov · Last updated 12 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis. The trial will be conducted in approximately 30 interventional neurology centers in China. Currently, there is no consensus regarding the duration of DAPT after drug-eluting stent treatment for vertebral artery stenosis(VAS). The objective of this study is to standardize clinical medication by shortening the duration of DAPT, thereby reducing the bleeding risk and medication burden for patients, while ensuring that there is no increase in ischemic events.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 520 (estimated)
- First submitted
- 5 Nov 2024
- Start date
- Nov 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT06683300
What you commit to
- Study type: Observational
- Planned participants: 520
- From Nov 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with aneurysms that cannot be treated in advance or at the same time or are not suitable for surgery;
- Interventional or surgical procedures are planned within 90 days;
Other illness
- Severe coagulation dysfunction, serious uncontrolled infection, serious systemic disease, uncontrolled hypertension, etc., are not suitable for surgery;
- Myocardial infarction or large-scale cerebral infarction occurred within 2 weeks;
- Combined with atrial fibrillation, or accompanied by serious heart, liver, kidney and lung diseases;
Other
- Known contraindications to heparin, rapamycin, anesthesia and contrast agents;
- Life expectancy is less than 12 months;
- The researcher considers it inappropriate to participate in this study.
Who the study is looking for
- Age ≥18 years old, gender unlimited;
- Based on clinical and imaging evidence, the investigators identified patients with symptomatic vertebral atherosclerotic stenosis who met the indications for the placement of drug-eluting vertebral artery stents;
- Patients or their guardians sign informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.